- Home
- LCTX vs AJX Comparison
LCTX vs AJX Comparison
Compare LCTX & AJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- AJX
- Stock Information
- Founded
- LCTX 1990
- AJX 2014
- Country
- LCTX United States
- AJX United States
- Employees
- LCTX N/A
- AJX N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- AJX Real Estate Investment Trusts
- Sector
- LCTX Health Care
- AJX Real Estate
- Exchange
- LCTX Nasdaq
- AJX Nasdaq
- Market Cap
- LCTX 166.3M
- AJX 141.2M
- IPO Year
- LCTX N/A
- AJX 2015
- Fundamental
- Price
- LCTX $0.91
- AJX $3.12
- Analyst Decision
- LCTX Strong Buy
- AJX Buy
- Analyst Count
- LCTX 3
- AJX 2
- Target Price
- LCTX $5.67
- AJX $6.00
- AVG Volume (30 Days)
- LCTX 442.0K
- AJX 142.0K
- Earning Date
- LCTX 11-14-2024
- AJX 10-21-2024
- Dividend Yield
- LCTX N/A
- AJX 7.74%
- EPS Growth
- LCTX N/A
- AJX N/A
- EPS
- LCTX N/A
- AJX N/A
- Revenue
- LCTX $6,186,000.00
- AJX N/A
- Revenue This Year
- LCTX N/A
- AJX N/A
- Revenue Next Year
- LCTX $123.52
- AJX N/A
- P/E Ratio
- LCTX N/A
- AJX N/A
- Revenue Growth
- LCTX N/A
- AJX N/A
- 52 Week Low
- LCTX $0.77
- AJX $2.98
- 52 Week High
- LCTX $1.61
- AJX $6.01
- Technical
- Relative Strength Index (RSI)
- LCTX 55.63
- AJX 46.61
- Support Level
- LCTX $0.88
- AJX $3.00
- Resistance Level
- LCTX $0.97
- AJX $3.20
- Average True Range (ATR)
- LCTX 0.04
- AJX 0.10
- MACD
- LCTX 0.01
- AJX 0.00
- Stochastic Oscillator
- LCTX 71.56
- AJX 35.29
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About AJX Great Ajax Corp.
Great Ajax Corp is an externally managed real estate company. The company's primary business is acquiring, investing in and managing a portfolio of mortgage loans. The company is focused on acquisitions of re-performing loans (RPLs) including residential mortgage loans and small balance commercial mortgage loans (SBC loans). Great Ajax operates in a single segment. The company also holds real-estate owned (REO) properties acquired upon the foreclosure, other settlement of owned non-performing loans.